19 September 2023- interim results
The AIM-listed medical technology group has announced its interim results for the six months to 30 June and these have disappointed investors. Despite a modest increase in revenue for the period to £5.65m (2022: 2£5.41m), a reduction in margins meant that an adjusted pre-tax loss of £204k (2022: adj.pre-tax profit of 72k) was recorded. At the end of the period the company had net cash balances of £0.38m (2022: £0.99m) although this was partly due to the group carrying higher levels of inventory than normal to . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
